Therapies: PharmaEssentia Ensures Reliable Interferon Access

Therapies: PharmaEssentia Ensures Reliable Interferon Access PharmaEssentia (TWSE: 6446), a leading global biopharmaceutical company, has reaffirmed its commitment to ensuring robust and reliable access to critical interferon therapies, particularly in light of the reported global shortage of Pegasys® (peginterferon alfa-2a).…

Read MoreTherapies: PharmaEssentia Ensures Reliable Interferon Access

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS Voom™ Medical Devices, Inc. (“Voom”), a pioneering company revolutionizing minimally invasive foot and ankle surgery, is excited to announce that its Founder and CEO,…

Read MoreVoom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS

Invests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital

Invests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital Hamershlag Private Capital Management Limited (HPCM), a prominent health technology investment firm, invests in Patho Care, LLC, a leading innovator in non-invasive point-of-care diagnostic testing. Patho Care’s groundbreaking Raman…

Read MoreInvests $150M in Patho Care via PathoCare Holdings, Hamershlag Private Capital
Analgesic

Analgesic from Xgene Pharmaceutical Reduces Pain and Opioid Use in Post-Surgical Trial

Analgesic from Xgene Pharmaceutical Reduces Pain and Opioid Use in Post-Surgical Trial Xgene Pharmaceutical has revealed further findings from a positive, multi-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) evaluating the safety and efficacy of its XG005 oral tablet…

Read MoreAnalgesic from Xgene Pharmaceutical Reduces Pain and Opioid Use in Post-Surgical Trial

Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer

Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)…

Read MoreVerastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer